Metformin: historical overview.
Level 5 - mechanism / opinion, no new human data
Narrative review and historical overview without original empirical data or systematic search methodology.
PubMed 28776081 · doi:10.1007/s00125-017-4318-z
What was done
Narrative review and historical overview summarizing the discovery, synthesis, clinical adoption, and regulatory milestones of metformin from its botanical origins (Galega officinalis) to its role in modern type 2 diabetes management.
What was found
The abstract reports a historical timeline without quantitative experimental data. Key milestones include: guanidine was shown to lower blood glucose in 1918; metformin was investigated for influenza and antimalarial properties in the 1940s; Jean Sterne first reported its use for diabetes in 1957; competing biguanides (phenformin and buformin) were discontinued in the late 1970s due to lactic acidosis risk; metformin entered the US market in 1995; and the UK Prospective Diabetes Study (UKPDS) identified long-term cardiovascular benefits in 1998, establishing it as first-line therapy.
Why it matters
Contextualizes how metformin overcame safety concerns associated with the biguanide drug class to become the most widely prescribed oral glucose-lowering therapy worldwide.
Limits
As an editorial and historical narrative, this publication contains no new empirical patient data, systematic search protocol, or quantitative statistical analysis.
Cited by
- supports Metformin is a type 2 diabetes medication that has been in clinical use for approximately 80 years to lower blood sugar.